Nanogen, Inc announced today that it has sold 4.25 million shares of its common stock to institutional investors at a price of $7.94 per share, for gross proceeds of approximately $33.7 million. After deducting fees and expenses, Nanogen will receive approximately $31.5 million from the sale, which is being conducted pursuant to Nanogen's shelf registration statement filed in January 2004. The sale is expected to close on or about Friday, March 5, 2004. Nanogen plans to use the net proceeds for working capital, including the pending SYN X Pharma acquisition, and other general corporate purposes. Seven Hills Partners LLC acted as exclusive placement agent to Nanogen for this financing.
"This financing further strengthens our balance sheet and provides additional capital to accelerate our entry into the point-of-care diagnostics market, which began with our recent agreement to acquire SYN X Pharma," said Howard C. Birndorf, chairman and CEO of Nanogen. "The financing will also support our long-term strategy to commercialize advanced medical diagnostics and help pave the way for Nanogen to enter new, synergistic markets."
Posted 5th March 2004
Please use one of the following formats to cite this article in your essay, paper or report:
Nanogen. (2013, June 11). Nanogen Announces $34 Million Common Stock Sale - News Item. AZoNano. Retrieved on June 01, 2023 from https://www.azonano.com/article.aspx?ArticleID=623.
Nanogen. "Nanogen Announces $34 Million Common Stock Sale - News Item". AZoNano. 01 June 2023. <https://www.azonano.com/article.aspx?ArticleID=623>.
Nanogen. "Nanogen Announces $34 Million Common Stock Sale - News Item". AZoNano. https://www.azonano.com/article.aspx?ArticleID=623. (accessed June 01, 2023).
Nanogen. 2013. Nanogen Announces $34 Million Common Stock Sale - News Item. AZoNano, viewed 01 June 2023, https://www.azonano.com/article.aspx?ArticleID=623.
Do you have a review, update or anything you would like to add to this article?
Cancel reply to comment
Dr. Jeffrey Dick
In this interview conducted at Pittcon 2023 in Philadelphia, Pennsylvania, we spoke to Dr. Jeffrey Dick about his work studying the chemistry of small volumes and nano-electrochemical tools.
Here, AZoNano speaks with Dirigent Acoustics about the benefits graphene could bring to acoustic and audio technologies and how the company's relationship with the Graphene Flagship has shaped its success.
In this interview, KLA's Bryan Crawford explains everything there is to know about nanoindentation, the challenges that the field currently faces, and how they can be overcome.
The Diamond Interaction Chamber (DIXC) is integral to the NanoGenizer high-pressure homogenizer.
The new AUTOsample-100 mounting autosampler is compatible with the 100 MHz benchtop NMR spectrometer.
The Vistec SB3050-2 is the most advanced electron beam lithography system with variable-shaped beam technology, allowing a wide range of applications in research and development, prototyping, and small-volume production.